Case Caption: In re Integra Lifesciences Holdings Corporation Securities Litigation
Court: District of New Jersey
Case Number: No. 3:23-cv-20321-MAS-TJB
Judge: Hon. Michael A. Shipp
Plaintiff: San Antonio Fire and Police Pension Fund; Pembroke Pines Firefighters & Police Officers Pension Fund; City of Birmingham Retirement and Relief System; and Operating Engineers Construction Industry and Miscellaneous Pension Fund
Defendant: Integra LifeSciences Holdings Corporation ("Integra"), Carrie Anderson, Peter Arduini, Glenn Coleman, Jan De Witte, Robert Davis, Lea Knight, Steve Leonard, Tracy Redondo, and Eric Schwartz
Class Period: March 11 2019 to July 28, 2024, inclusive
This case arises from Defendants’ fraudulent scheme to conceal systemic violations of current Good Manufacturing Practices (“cGMP”) at Integra’s critical Boston, Massachusetts facility, where the Company manufactured biologic mesh medical devices—its most lucrative product line—derived from bovine tissue and implanted in patients requiring skin substitutes or tissue recovery.
At the beginning of the Class Period, the FDA issued Integra a Warning Letter identifying serious cGMP violations at the Boston Facility, including failures to prevent dangerous bacterial and fungal contamination during the manufacturing process. Defendants repeatedly assured investors that they were actively remediating these deficiencies, that patient safety was not at risk, and that the Boston Facility’s manufacturing and shipping operations remained unaffected.
Lead Plaintiffs contend that Defendants knew these statements were false. As alleged in the Consolidated Supplemental Amended Complaint filed by Lead Plaintiff on March 13, 2026 (the “Complaint”), rather than undertaking meaningful remediation, Defendants—including then-CEO Jan De Witte, then-Chief Legal Officer Eric Schwartz, and other members of Integra’s Executive Leadership Team—resolved to do the “least amount possible with the least amount of money” to keep the Boston Facility in production and protect its high-margin products. The Complaint alleges that Defendants instituted only superficial fixes, slashed the Quality team’s budget and headcount, and silenced internal dissent through verbal abuse, threats, withheld compensation, and termination. The alleged fraudulent scheme is detailed in two whistleblower actions filed by former senior quality officials, which are detailed in the Complaint.
The truth about Defendants’ alleged scheme was gradually revealed to the market between April 2023 and July 2024, through a series of corrective disclosures that included a costly production halt at the Boston Facility, a global recall of all products manufactured there for more than five years, and production and shipping halts across all Company facilities while Integra’s Board instituted a “compliance master plan” to address systemic quality and cGMP deficiencies across the entire organization. In response to these disclosures, Integra’s stock price collapsed by nearly 67% from its Class Period high.
Lead Plaintiffs have opposed Defendants’ motion to dismiss, including engaging in supplemental briefing regarding newly unsealed allegations from the whistleblower actions described above. Defendants’ motion remains pending before the Court.